Citation

Qin J. Journal of International Pharmaceutical Research 2012; (6): 409-413.

Copyright

(Copyright © 2012)

DOI

unavailable

PMID

unavailable

Abstract

Depression is an affective disorder with high prevalence. high suicide rate and low treatment rate. its neurobiologi-cal mechanism remains unclear. Most of current first-line antidepressants are based on the "monoamine hypothesis", including monoamine reuptake inhibitors, monoamine oxidase inhibitors and monoamine receptor ligand drugs. Although their therapeutic effect is definite, there are still serious defects. such as low response and delayed onset. It has been widely confirmed that depression is closely related to low serotonin (5-hydroxytryptamine, 5-HT) neurotransmission function (classical monoamine hypothesis), while modern monoamine theory suggests that the adaptability and plasticity regulation of 5-HT and its autoreceptors (such as 5-HT1A) are closely related to the treatment of depression. There are a series of new progress in recent years in the studies of 5-HT transporter proteins and 5-HT receptors, such as the positive role of S allele of the 5-HT transporter chain area in emotion and cognition, and the discoveries of the pharmacological basement of some new 5-HT-related receptor antagonists or agonists. There are also important breakthroughs in sero-tonineigic drug research and development (such as vilazodone, which approved by the US FDA in 2011, is a dual-target drug of 5-HT1A partial agonist and 5-HT reuptake inhibitor). In this review, the recent research progress on the relationship of 5-HT neuromodulation and depression is summarized. © 2006 Editorial office of Foreign Medical Sciences.

Language: zh

Keywords

Depression; 5-hydroxytryptamine; Receptor; Transporter